The aminopeptidase inhibitor CHR-2863 is an orally bioavailable inhibitor of murine malaria
- Publication Type:
- Journal Article
- Antimicrobial Agents and Chemotherapy, 2012, 56 (6), pp. 3244 - 3249
- Issue Date:
Files in This Item:
|Antimicrob. Agents Chemother.-2012-Skinner-Adams-3244-9.pdf||Published Version||810.61 kB|
Copyright Clearance Process
- Recently Added
- In Progress
- Open Access
This item is open access.
Malaria remains a significant risk in many areas of the world, with resistance to the current antimalarial pharmacopeia an everincreasing problem. The M1 alanine aminopeptidase (PfM1AAP) and M17 leucine aminopeptidase (PfM17LAP) are believed to play a role in the terminal stages of digestion of host hemoglobin and thereby generate a pool of free amino acids that are essential for parasite growth and development. Here, we show that an orally bioavailable aminopeptidase inhibitor, CHR-2863, is efficacious against murine malaria. Copyright © 2012, American Society for Microbiology. All Rights Reserved.
Please use this identifier to cite or link to this item: